Related Experiment Video
Updated: Aug 6, 2026

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
Published on: February 13, 2021
Guideline for the management of heart failure caused by systolic dysfunction: part II. Treatment
W E Chavey1, C S Blaum, B E Bleske
1University of Michigan, Ann Arbor, USA.
Insights
Pharmacologic interventions significantly reduce heart failure morbidity and mortality. Key treatments for left ventricular systolic dysfunction include ACE inhibitors, beta blockers, and spironolactone, improving patient outcomes.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Heart failure management has evolved, moving beyond symptom control to reducing morbidity and mortality.
- Large clinical trials over the past decade have established effective pharmacologic interventions.
Framework:
- This article presents treatment recommendations for left ventricular systolic dysfunction (LVSD).
- Focuses on evidence-based pharmacologic strategies to improve heart failure outcomes.
Implementation:
- Recommend angiotensin-converting enzyme inhibitors for all LVSD patients.
- Advise beta blockers for all except those with resting symptoms.
- Suggest spironolactone for patients with current or recent resting symptoms.
Implications:
- These interventions enhance the therapeutic paradigm for heart failure.
- Optimized pharmacotherapy can significantly improve patient prognosis and quality of life.
- Diuretics and digoxin are reserved for symptomatic management.
Abstract:
Several large clinical trials conducted over the past decade have shown that pharmacologic interventions can dramatically reduce the morbidity and mortality associated with heart failure. These trials have modified and enhanced the therapeutic paradigm for heart failure and extended treatment goals beyond limiting congestive symptoms of volume overload. Part II of this two-part article presents treatment recommendations for patients with left ventricular systolic dysfunction. The authors recommend that, if tolerated and not contraindicated, the following agents be used in patients with left ventricular systolic dysfunction: an angiotensin-converting enzyme inhibitor in all patients; a beta blocker in all patients except those who have symptoms at rest; and spironolactone in patients who have symptoms at rest or who have had such symptoms within the past six months. Diuretics and digoxin should be reserved, as needed, for symptomatic management of heart failure. Other treatments or treatment programs may be necessary in individual patients.
Related Concept Videos
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Heart Failure II: Pathophysiology
Heart Failure IV: Classification and Diagnostic Evaluation
Heart Failure V: Medical Management
Heart Failure VI: Adjunct Therapies
Heart Failure VII: Nursing Interventions

